Analysis of the immune response using FTIR spectroscopy in mothers and their newborns with different vaccination schemes for COVID-19.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      COVID-19*/prevention & control ; COVID-19*/immunology ; Vaccination*/methods ; SARS-CoV-2*/immunology ; COVID-19 Vaccines*/immunology; Humans ; Female ; Spectroscopy, Fourier Transform Infrared/methods ; Infant, Newborn ; Pregnancy ; Adult ; Mothers ; Antibodies, Viral/immunology ; Antibodies, Viral/blood ; Antibodies, Viral/analysis ; Immunity, Humoral ; Saliva/immunology ; Immunity, Cellular ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Immunoglobulin A/immunology ; Immunoglobulin A/analysis ; Interferon-gamma/metabolism ; mRNA Vaccines/immunology
    • Abstract:
      The SARS-CoV-2 outbreak has provoked more than 6 million deaths worldwide. The scarcity of effective treatments and its virulence converted the vaccines into an essential tool to face it. The most used vaccines were the mRNA, adenovirus vector, and inactivated whole-virus. However, nowadays, infants aged < 6 months are not eligible for any vaccines against COVID-19, and their immunization relies on passive immunity. In this research, we investigated the humoral and cellular immune response generated on newborns of SARS-CoV-2 vaccinated mothers with mRNA or viral vector (VV) vaccine employing Fourier transformed infrared (FTIR) spectroscopy in saliva samples. For this purpose, saliva samples of newborns and their mothers were collected; the population was divided into two groups, VV and mRNA, which were subdivided into three subgroups: before pregnancy (BP), at the first (FTP) and second (STP) trimesters of pregnancy. The samples were analyzed using FTIR spectroscopy, and the bands associated with the humoral and cellular immune responses, such as IgG, IgA, and IFN-γ were analyzed. The integrated areas were calculated and compared to elucidate the quantity of those immunoglobins and the cytokine. Likewise, the correlation of the humoral and cellular immune response between the newborns and their mothers and the correlation between cellular and humoral immune response was also evaluated. The VV vaccine produced a significant humoral and cellular immune response in newborns and their mothers when they received it at the STP compared with the mRNA vaccine, evidencing statistical significance. However, no correlation was observed between newborns and their mothers when the vaccine was applied in this trimester of pregnancy. When administered BP, the mRNA vaccine generated more humoral immunity in newborns and their mothers. Nevertheless, compared with the VV vaccine, it only showed statistical significance in the mothers, highlighting that IgG showed a moderate positive correlation between the newborns and their mothers.
      (© 2024. The Author(s).)
    • References:
      Int J Mol Sci. 2015 Dec 18;16(12):30223-50. (PMID: 26694380)
      Vaccines (Basel). 2021 Aug 03;9(8):. (PMID: 34451973)
      Cells. 2022 Dec 01;11(23):. (PMID: 36497139)
      J Dent Res. 2005 Jan;84(1):29-34. (PMID: 15615871)
      PLoS One. 2012;7(8):e43419. (PMID: 22916257)
      Nat Commun. 2022 Aug 18;13(1):4855. (PMID: 35982045)
      Obstet Gynecol. 2022 Mar 1;139(3):373-380. (PMID: 34963127)
      Pediatr Dent. 1989 Mar;11(1):30-6. (PMID: 2626337)
      Rheumatol Int. 2022 Mar;42(3):449-456. (PMID: 35059799)
      Eur J Clin Microbiol Infect Dis. 2023 Mar;42(3):277-285. (PMID: 36692603)
      Nat Commun. 2022 Sep 12;13(1):5359. (PMID: 36097164)
      Front Public Health. 2023 Jan 12;10:960598. (PMID: 36711369)
      Clin Dev Immunol. 2012;2012:985646. (PMID: 22235228)
      Viruses. 2023 Feb 24;15(3):. (PMID: 36992330)
      Signal Transduct Target Ther. 2023 Apr 7;8(1):149. (PMID: 37029123)
      J Nat Med. 2018 Jan;72(1):32-42. (PMID: 29164507)
      Front Immunol. 2020 Oct 07;11:575197. (PMID: 33133091)
      JAMA Pediatr. 2022 Mar 01;176(3):290-295. (PMID: 34932066)
      Nat Commun. 2023 Feb 28;14(1):894. (PMID: 36854660)
      Immunohorizons. 2018 Jan 1;2(1):14-25. (PMID: 29457151)
      Am J Clin Nutr. 1984 Apr;39(4):584-8. (PMID: 6608871)
      Clin Chem Lab Med. 2009;47(1):83-90. (PMID: 19117408)
      Microorganisms. 2022 Jul 18;10(7):. (PMID: 35889169)
      Micromachines (Basel). 2022 Jan 26;13(2):. (PMID: 35208311)
      Sci Rep. 2021 Oct 7;11(1):19980. (PMID: 34620977)
      Sci Rep. 2020 Nov 30;10(1):20818. (PMID: 33257702)
      Front Immunol. 2020 May 19;11:855. (PMID: 32508816)
      J Med Virol. 2023 Jan;95(1):e28296. (PMID: 36367230)
      Front Immunol. 2022 Jun 01;13:859019. (PMID: 35720318)
      Nat Med. 2023 May;29(5):1164-1171. (PMID: 36973410)
      Early Hum Dev. 2001 May;62(2):159-64. (PMID: 11282225)
      Vaccines (Basel). 2022 Nov 15;10(11):. (PMID: 36423025)
      BMJ. 2022 Aug 10;378:e069741. (PMID: 35948352)
      Arch Oral Biol. 1984;29(5):357-62. (PMID: 6204626)
      N Engl J Med. 2022 Jul 14;387(2):109-119. (PMID: 35731908)
    • Accession Number:
      0 (COVID-19 Vaccines)
      0 (Antibodies, Viral)
      0 (Immunoglobulin G)
      0 (Immunoglobulin A)
      82115-62-6 (Interferon-gamma)
      0 (mRNA Vaccines)
    • Publication Date:
      Date Created: 20240727 Date Completed: 20240728 Latest Revision: 20240806
    • Publication Date:
      20240806
    • Accession Number:
      PMC11283522
    • Accession Number:
      10.1038/s41598-024-68340-8
    • Accession Number:
      39068230